Cargando…
Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis
Background and objectives—Chronic viral hepatitis B and C infections are one of the leading causes of chronic liver impairment, resulting in liver fibrosis and liver cirrhosis. An early diagnosis with accurate liver fibrosis staging leads to a proper diagnosis, thus tailoring correct treatment. Both...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612220/ https://www.ncbi.nlm.nih.gov/pubmed/36295494 http://dx.doi.org/10.3390/medicina58101333 |
_version_ | 1784819720445231104 |
---|---|
author | Jocius, Donatas Vajauskas, Donatas Mikelis, Kipras Jokubauskiene, Skirmante Jakutiene, Jolita Strupas, Kestutis Tamosiunas, Algirdas E. |
author_facet | Jocius, Donatas Vajauskas, Donatas Mikelis, Kipras Jokubauskiene, Skirmante Jakutiene, Jolita Strupas, Kestutis Tamosiunas, Algirdas E. |
author_sort | Jocius, Donatas |
collection | PubMed |
description | Background and objectives—Chronic viral hepatitis B and C infections are one of the leading causes of chronic liver impairment, resulting in liver fibrosis and liver cirrhosis. An early diagnosis with accurate liver fibrosis staging leads to a proper diagnosis, thus tailoring correct treatment. Both invasive and noninvasive techniques are used in the diagnosis and staging of chronic liver impairment. Those techniques include liver biopsy, multiple serological markers (as either single tests or combined panels), and imaging examinations, such as ultrasound or magnetic resonance elastography. Nuclear medicine probes may also be employed in staging liver fibrosis, although the literature scarcely reports this. The purpose of our study was to investigate whether a dynamic liver scintigraphy with [(99m)Tc]Tc-mebrofenin has any value in staging or grading chronic liver damage. Materials and Methods—We prospectively enrolled patients with chronic viral hepatitis B and C infection referred for liver biopsy. All patient underwent dynamic liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy. Dynamic liver scintigraphy was performed immediately after intravenous tracer injection for 30 min scanning time. Multiple scintigraphy parameters were calculated (whole liver lobe and focal area time to peak (TTP), 30 min to peak ratio (30/peak), whole lobe and focal area slope index in 350 s (slope_350). Liver biopsy took place shortly after imaging. Results—We found that many dynamic scintigraphic parameters are positively or negatively associated with different stages of liver fibrosis. The main parameters that showed most value are the ratio between 30 min and the peak of the dynamic curve (30/peak_dex (ratio)), and liver clearance corrected for body surface area and liver area (LCL_m(2)_dm(2) (%/min/m(2)/dm(2))). Conclusions—Our present study proves that conducting dynamic liver scintigraphies with [(99m)Tc]Tc-mebrofenin has potential value in staging liver fibrosis. The benefits of this method, including whole liver imaging and direct imaging of the liver function, provide an advantage over presently used quantitative imaging modalities. |
format | Online Article Text |
id | pubmed-9612220 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96122202022-10-28 Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis Jocius, Donatas Vajauskas, Donatas Mikelis, Kipras Jokubauskiene, Skirmante Jakutiene, Jolita Strupas, Kestutis Tamosiunas, Algirdas E. Medicina (Kaunas) Article Background and objectives—Chronic viral hepatitis B and C infections are one of the leading causes of chronic liver impairment, resulting in liver fibrosis and liver cirrhosis. An early diagnosis with accurate liver fibrosis staging leads to a proper diagnosis, thus tailoring correct treatment. Both invasive and noninvasive techniques are used in the diagnosis and staging of chronic liver impairment. Those techniques include liver biopsy, multiple serological markers (as either single tests or combined panels), and imaging examinations, such as ultrasound or magnetic resonance elastography. Nuclear medicine probes may also be employed in staging liver fibrosis, although the literature scarcely reports this. The purpose of our study was to investigate whether a dynamic liver scintigraphy with [(99m)Tc]Tc-mebrofenin has any value in staging or grading chronic liver damage. Materials and Methods—We prospectively enrolled patients with chronic viral hepatitis B and C infection referred for liver biopsy. All patient underwent dynamic liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy. Dynamic liver scintigraphy was performed immediately after intravenous tracer injection for 30 min scanning time. Multiple scintigraphy parameters were calculated (whole liver lobe and focal area time to peak (TTP), 30 min to peak ratio (30/peak), whole lobe and focal area slope index in 350 s (slope_350). Liver biopsy took place shortly after imaging. Results—We found that many dynamic scintigraphic parameters are positively or negatively associated with different stages of liver fibrosis. The main parameters that showed most value are the ratio between 30 min and the peak of the dynamic curve (30/peak_dex (ratio)), and liver clearance corrected for body surface area and liver area (LCL_m(2)_dm(2) (%/min/m(2)/dm(2))). Conclusions—Our present study proves that conducting dynamic liver scintigraphies with [(99m)Tc]Tc-mebrofenin has potential value in staging liver fibrosis. The benefits of this method, including whole liver imaging and direct imaging of the liver function, provide an advantage over presently used quantitative imaging modalities. MDPI 2022-09-23 /pmc/articles/PMC9612220/ /pubmed/36295494 http://dx.doi.org/10.3390/medicina58101333 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jocius, Donatas Vajauskas, Donatas Mikelis, Kipras Jokubauskiene, Skirmante Jakutiene, Jolita Strupas, Kestutis Tamosiunas, Algirdas E. Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis |
title | Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis |
title_full | Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis |
title_fullStr | Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis |
title_full_unstemmed | Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis |
title_short | Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [(99m)Tc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis |
title_sort | quantitative assessment of liver impairment in chronic viral hepatitis with [(99m)tc]tc-mebrofenin: a noninvasive attempt to stage viral hepatitis-associated liver fibrosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612220/ https://www.ncbi.nlm.nih.gov/pubmed/36295494 http://dx.doi.org/10.3390/medicina58101333 |
work_keys_str_mv | AT jociusdonatas quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis AT vajauskasdonatas quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis AT mikeliskipras quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis AT jokubauskieneskirmante quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis AT jakutienejolita quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis AT strupaskestutis quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis AT tamosiunasalgirdase quantitativeassessmentofliverimpairmentinchronicviralhepatitiswith99mtctcmebrofeninanoninvasiveattempttostageviralhepatitisassociatedliverfibrosis |